These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 27566331)

  • 1. BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?
    Bhatt H; Ghazi L; Calhoun D; Oparil S
    Curr Cardiol Rep; 2016 Oct; 18(10):98. PubMed ID: 27566331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Hypertension: Which Goal for Which Patient?
    Jarraya F
    Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the SPRINT Trial on Hypertension Management.
    Ghazi L; Oparil S
    Annu Rev Med; 2018 Jan; 69():81-95. PubMed ID: 29414255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morning Home Blood Pressure and Cardiovascular Events in Japanese Hypertensive Patients.
    Kario K; Iwashita M; Okuda Y; Sugiyama M; Saito I; Kushiro T; Teramukai S; Shimada K
    Hypertension; 2018 Oct; 72(4):854-861. PubMed ID: 30354719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals (summary). Joint recommendations from the International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk (SECAC), Spanish Society of Atherosclerosis (SEA), and Romanian Society of Internal Medicine (RSIM)].
    Hermida RC; Smolensky MH; Ayala DE; Portaluppi F; Crespo JJ; Fabbian F; Haus E; Manfredini R; Mojón A; Moyá A; Piñeiro L; Ríos MT; Otero A; Balan H; Fernández JR
    Clin Investig Arterioscler; 2013; 25(2):74-82. PubMed ID: 23849214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies.
    Gosmanova EO; Kovesdy CP
    Curr Cardiol Rep; 2016 Sep; 18(9):88. PubMed ID: 27448402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive systolic blood pressure control in older subjects: benefits and risks.
    Chrysant SG
    Postgrad Med; 2018 Mar; 130(2):159-165. PubMed ID: 29375010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines.
    Egan BM; Li J; Wagner CS
    Hypertension; 2016 Aug; 68(2):318-23. PubMed ID: 27354422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should blood pressure goal be individualized in hypertensive patients?
    Yannoutsos A; Kheder-Elfekih R; Halimi JM; Safar ME; Blacher J
    Pharmacol Res; 2017 Apr; 118():53-63. PubMed ID: 27919826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data.
    Vlachopoulos C; Terentes-Printzios D; Aznaouridis K; Ioakeimidis N; Xaplanteris P; Lazaros G; Tousoulis D
    Curr Vasc Pharmacol; 2019; 17(3):298-306. PubMed ID: 29512468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
    Attar A; Sayadi M; Jannati M
    Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials.
    Heimark S; Mariampillai JE; Narkiewicz K; Nilsson PM; Kjeldsen SE
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):151-158. PubMed ID: 29663195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
    Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
    Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals.
    ; ; ; ; ; Hermida RC; Smolensky MH; Ayala DE; Portaluppi F
    Chronobiol Int; 2013 Apr; 30(3):355-410. PubMed ID: 23517220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease?
    Tyson CC; Coffman TM
    Nephron; 2017; 135(4):287-290. PubMed ID: 28161697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.
    Sarafidis PA; Lazaridis AA; Ruiz-Hurtado G; Ruilope LM
    Nat Rev Endocrinol; 2017 Jun; 13(6):365-374. PubMed ID: 28106149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalizability of SPRINT Results to the U.S. Adult Population.
    Bress AP; Tanner RM; Hess R; Colantonio LD; Shimbo D; Muntner P
    J Am Coll Cardiol; 2016 Feb; 67(5):463-72. PubMed ID: 26562046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.